Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

por Joulain, F, Proskorovsky, I, Allegra, C, Tabernero, J, Hoyle, M, Iqbal, S U, Van Cutsem, E
Publicado 2013

Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial

por Kansal, A., Reifsnider, O. S., Proskorovsky, I., Zheng, Y., Pfarr, E., George, J. T., Kandaswamy, P., Ruffolo, A.
Publicado 2019